[
    [
        {
            "time": "2019-04-30",
            "original_text": "【国元医药】康泰生物2019年报&2020Q1季报点评：一季度疫情影响较大，静待后续重磅品种问世",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019年报",
                    "2020Q1",
                    "疫情影响",
                    "重磅品种"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【国元医药】康泰生物2019年报&2020Q1季报点评：一季度疫情影响较大，静待后续重磅品种问世",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-30",
            "original_text": "【康泰生物|年报点评】20Q1业绩受疫情短期影响，2020全年业绩高增长可期【安信医药马帅团队】",
            "features": {
                "keywords": [
                    "康泰生物",
                    "20Q1",
                    "疫情",
                    "短期影响",
                    "全年高增长"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【康泰生物|年报点评】20Q1业绩受疫情短期影响，2020全年业绩高增长可期【安信医药马帅团队】",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-30",
            "original_text": "康泰生物：一季度营收、净利双下滑 同比分别减少48.12%和97.57% 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "一季度",
                    "营收下滑",
                    "净利下滑",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：一季度营收、净利双下滑 同比分别减少48.12%和97.57% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04-30",
            "original_text": "康泰生物（300601）：疫情不改全年高增长趋势，定增奠定中长期发展基础【2019年报点评|西南医药朱国广/杜向阳团队】",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫情",
                    "全年高增长",
                    "定增",
                    "中长期发展"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物（300601）：疫情不改全年高增长趋势，定增奠定中长期发展基础【2019年报点评|西南医药朱国广/杜向阳团队】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-05-10",
            "original_text": "融资客青睐6股，江河集团买入占比高达43.15%",
            "features": {
                "keywords": [
                    "融资客",
                    "江河集团",
                    "买入占比"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "其他"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "融资客青睐6股，江河集团买入占比高达43.15%",
                "Correlation": 1,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-04-30",
            "original_text": "康泰生物(300601.SZ)：一季度净利降97.57%至242.42万元 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "一季度",
                    "净利降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)：一季度净利降97.57%至242.42万元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-31",
            "original_text": "疫苗研发企业康泰生物2019净利润5.75亿元",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019",
                    "净利润",
                    "疫苗研发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "疫苗研发企业康泰生物2019净利润5.75亿元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-03-31",
            "original_text": "康泰生物：2019年净利润同比增长31.86%",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：2019年净利润同比增长31.86%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-30",
            "original_text": "康泰生物：一季度净利润同比减少97.57% 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "一季度",
                    "净利润",
                    "同比减少",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：一季度净利润同比减少97.57% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]